Semaglutide for the Treatment of Cannabis Use Disorder

What Was Tested

This registered phase 2 trial tested Semaglutide.

The goal of this pilot study is to learn about the effects of semaglutide on brain reactivity to cannabis-related cues in adults with cannabis use disorder.

The main questions it aims to answer are: 1.

Does semaglutide effect reactivity to cannabis-related cues? 2.

It had 1 arm (groups): Semaglutide (experimental).

Participants in this single arm, open-label pilot trial will receive semaglutide administered as a once-weekly subcutaneous injection for 8 weeks. Participants will complete five in-person study visits over 9 weeks. Study visits will include interviews, questionnaires, and collection of biological samples for laboratory testing. Pre- and post-treatment fMRI scans will be completed at Visits 2 and 4.

The registry classes the interventions as drug.

Who Took Part

The registry lists 40 planned participants were the target.

It was open to people of any sex aged from 18 years up to 60 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Adults aged 18-60 years, inclusive;. Use cannabis daily or near daily and have been using cannabis consistently for at least the past year, by self-report;. Diagnosed with moderate to severe DSM-5 cannabis use disorder. Access to a mobile device to complete daily surveys. Be able to read, speak, and understand the English language. English can be a second language provided that the subject understands all the questions used in the assessment measures.

The full record lists 6 inclusion and 22 exclusion criteria; among the exclusions: any current or lifetime diagnosis of eating disorders including anorexia, bulimia, or binge eating;; any current substance use disorder other than cannabis or mild alcohol use disorder;; BMI \<21 kg/m2;.

How the Study Was Run

It was run as a single-group and open-label study.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2027-01-10 with completion listed for 2029-01-30.

Its stated primary purpose is basic science.

What Was Measured

The main thing measured (primary outcome): Cannabis cue-reactivity (time frame: Baseline (pre-intervention), 8 weeks). Resting state connectivity (time frame: Baseline (pre-intervention), 8 weeks).

What This Means in Plain Language

Put simply, this is a phase 2 trial of Semaglutide in 40 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.